AbbVie | ABBV - Current Liabilities


AbbVie reported $41.64B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Abbott USD 18.38B 1.88B Mar/2026
ALKERMES USD 662.09M 62.59M Jun/2026
Amgen USD 24.96B 534M Mar/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Coherus Biosciences USD 140.39M 231.91M Dec/2025
Eisai JPY 393.64B 53.39B Jun/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Gilead Sciences USD 9.48B 2.34B Mar/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Medtronic USD 9.5B 440M Dec/2025
Merck USD 26.94B 1.38B Mar/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Novartis USD 31.75B 374M Jun/2026
Pacira USD 108.79M 11.8M Mar/2026
Perrigo USD 997.6M 15.3M Mar/2026
Pfizer USD 32.65B 1.7B Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sanofi EUR 31.93B 1.92B Jun/2026
UCB EUR 4.4B 470M Dec/2025
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
United Therapeutics USD 599.1M 38.5M Mar/2026
Vertex Pharmaceuticals USD 3.94B 57.3M Jun/2026
Zoetis USD 2.05B 182M Mar/2026